Biosimilar developer Sandoz announced today that it has entered into a global partnership with India-based Biocon to develop, manufacture, and commercialize multiple biosimilars targeting immunology and oncology indications.
Biosimilar developer Sandoz announced today that it has entered into a global partnership with India-based Biocon to develop, manufacture, and commercialize multiple biosimilars targeting immunology and oncology indications.
Under the agreement, the companies will share responsibility for end-to-end development, manufacturing, and regulatory approvals for the products in question, and will share costs and profits. Sandoz will lead commercialization of approved biosimilars in North America and the European Union, while Biocon will commercialize the drugs in the rest of the world.
“Today’s announcement bolsters our leadership position in biosimilars and positions us to continue to lead well into the future,” said Richard Francis, CEO of Sandoz, in a statement. “Biocon is a great complement to our proven biosimilar capabilities at Sandoz. Through this collaboration, we are reinforcing our long-term commitment to increase patient access to biologics.”
Chairperson and managing director of Biocon, Kiran Mazumdar-Shaw, added, “This synergistic partnership will enable us to scale up our capabilities for an end-to-end play in the global biosimilars space.”
The agreement with Sandoz forms Biocon’s second partnership seeking to bring its biosimilars to the US and EU markets; Biocon successfully partnered with Mylan on a trastuzumab biosimilar, Ogivri, approved by the FDA in December 2017. Last week, at the 36th Annual J.P. Morgan Healthcare Conference, Rajiv Malik, company president of Mylan, hinted that Biocon—Mylan’s pegfilgrastim biosimilar could gain FDA approval by the middle of 2018. Both the trastuzumab and pegfilgrastim products are also under European regulatory review.
News of the Sandoz—Biocon partnership comes just days after Sandoz announced that the FDA has accepted for review its Biologics License Application (BLA) for a proposed adalimumab (Humira) biosimilar. The drug maker has already received FDA’s nod for its etanercept biosimilar (which will be marketed in the United States as Erelzi, though no launch date has been made public) and its filgrastim biosimilar (Zarxio). The FDA is currently considering a BLA for Sandoz’s rituximab biosimilar, and the drug maker reports that it will refile its BLA for a pegfilgrastim biosimilar in 2019.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.